Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 6/2018

01-06-2018 | Nephrology - Review

Sickle cell nephropathy: an update on pathophysiology, diagnosis, and treatment

Authors: Essa Hariri, Anthony Mansour, Andrew El Alam, Yazan Daaboul, Serge Korjian, Sola Aoun Bahous

Published in: International Urology and Nephrology | Issue 6/2018

Login to get access

Abstract

Sickle cell nephropathy is a major complication of sickle cell disease. It manifests in different forms, including glomerulopathy, proteinuria, hematuria, and tubular defects, and frequently results in end-stage renal disease (ESRD). Different pathophysiologic mechanisms have been proposed to explain the development of nephropathy in SCD, where hemolysis and vascular occlusion are the main contributors in the manifestations of this disease. Markers of renal injury, such as proteinuria and tubular dysfunction, have been associated with outcomes among patients with sickle cell nephropathy and provide means for early detection of nephropathy and screening prior to progression to renal failure. In small-sized clinical trials, hydroxyurea has demonstrated to be effective in slowing the progression to ESRD. Dialysis and renal transplantation represent the last resort for patients with sickle cell nephropathy. Nevertheless, despite the availability of diagnostic and therapeutic strategies, sickle cell nephropathy remains a challenging and under-recognized complication for patients with sickle cell disease.
Literature
1.
2.
3.
Day TG, Drasar ER, Fulford T, Sharpe CC, Thein SL (2012) Association between hemolysis and albuminuria in adults with sickle cell anemia. Haematologica 97:201–205CrossRefPubMedPubMedCentral
4.
Haymann JP, Stankovic K, Levy P, Avellino V, Tharaux PL, Letavernier E et al (2010) Glomerular hyperfiltration in adult sickle cell anemia: a frequent hemolysis associated feature. Clin J Am Soc Nephrol 5:756–761CrossRefPubMedPubMedCentral
5.
Drawz P, Ayyappan S, Nouraie M, Saraf S, Gordeuk V, Hostetter T et al (2015) Kidney disease among patients with sickle cell disease, hemoglobin SS and SC. Clin J Am Soc Nephrol 11:207–215CrossRefPubMedPubMedCentral
6.
7.
Kato GJ, Wang Z, Machado RF, Blackwelder WC, Taylor JG, Hazen SL (2009) Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death. Br J Haematol 145:506–513CrossRefPubMed
8.
Khamaisi M, Heyman SN (2009) The role of hypoxia and HIF-mediated hypoxia adaptive response in the progression of chronic kidney disease. Harefuah 148:721–726PubMed
9.
Heimlich JB, Speed JS, O’Connor PM, Pollock JS, Townes TM, Meiler SE et al (2016) Endothelin-1 contributes to the progression of renal injury in sickle cell disease via reactive oxygen species. Br J Pharmacol 173:386–395CrossRefPubMed
10.
Becker AM (2011) Sickle cell nephropathy: challenging the conventional wisdom. Pediatric Nephrol 26:2099–2109CrossRef
11.
12.
Gonzalez-Michaca L, Farrugia G, Croatt AJ, Alam J, Nath KA (2004) Heme: a determinant of life and death in renal tubular epithelial cells. Am J Physiol Renal Physiol 286:F370–F377CrossRefPubMed
13.
Tracz MJ, Alam J, Nath KA (2007) Physiology and pathophysiology of heme: implications for kidney disease. J Am Soc Nephrol 18:414–420CrossRefPubMed
14.
Juncos JP, Grande JP, Croatt AJ, Hebbel RP, Vercellotti GM, Katusic ZS et al (2010) Early and prominent alterations in hemodynamics, signaling, and gene expression following renal ischemia in sickle cell disease. Am J Physiol Renal Physiol 298:F892–F899CrossRefPubMedPubMedCentral
15.
Audard V, Moutereau S, Vandemelebrouck G, Habibi A, Khellaf M, Grimbert P et al (2014) First evidence of subclinical renal tubular injury during sickle-cell crisis. Orphanet J Rare Dis 9:67CrossRefPubMedPubMedCentral
16.
Deux J-F, Audard V, Brugières P, Habibi A, Manea E-M, Guillaud-Danis C et al (2017) Magnetic resonance imaging assessment of kidney oxygenation and perfusion during sickle cell vaso-occlusive crises. Am J Kidney Dis 69:51–59CrossRefPubMed
17.
18.
19.
Pitcock JA, Muirhead EE, Hatch FE, Johnson JG, Kelly BJ (1970) Early renal changes in sickle cell anemia. Arch Pathol 90:403–410PubMed
20.
Bhathena DB, Sondheimer JH (1991) The glomerulopathy of homozygous sickle hemoglobin (SS) disease: morphology and pathogenesis. J Am Soc Nephrol 1:1241–1252PubMed
21.
Bakir AA, Hathiwala SC, Ainis H, Hryhorczuk DO, Rhee HL, Levy PS et al (1987) Prognosis of the nephrotic syndrome in sickle glomerulopathy. Am J Nephrol 7:110–115CrossRefPubMed
22.
Marsenic O, Couloures KG, Wiley JM (2008) Proteinuria in children with sickle cell disease. Nephrol Dial Transplant 23:715–720CrossRefPubMed
23.
Sharpe CC, Thein SL (2011) Sickle cell nephropathy—a practical approach. Br J Haematol 155:287–297CrossRefPubMed
24.
Pham PT, Pham PC, Wilkinson AH, Lew SQ (2000) Renal abnormalities in sickle cell disease. Kidney Int 57:1–8CrossRefPubMed
25.
Guasch A, Navarrete J, Nass K, Zayas CF (2006) Glomerular involvement in adults with sickle cell hemoglobinopathies: prevalence and clinical correlates of progressive renal failure. J Am Soc Nephrol 17:2228–2235CrossRefPubMed
26.
27.
Sesso R, Almeida MA, Figueiredo MS, Bordin JO (1998) Renal dysfunction in patients with sickle cell anemia or sickle cell trait. Braz J Med Biol Res 31:1257–1262CrossRefPubMed
28.
Abdu A, Emokpae MA, Uadia PO, Kuliya-Gwarzo A (2011) Proteinuria among adult sickle cell anemia patients in Nigeria. Ann Afr Med 10:34–37CrossRefPubMed
29.
Aygun B, Mortier NA, Smeltzer MP, Hankins JS, Ware RE (2011) Glomerular hyperfiltration and albuminuria in children with sickle cell anemia. Pediatric Nephrol 26:1285–1290CrossRef
30.
Aleem A (2008) Renal abnormalities in patients with sickle cell disease: a single center report from Saudi Arabia. Saudi J Kidney Dis Transplant 19:194–199
31.
Hirschberg R (2010) Glomerular hyperfiltration in sickle cell disease. Clin J Am Soc Nephrol 5:748–749CrossRefPubMed
32.
Wigfall DR, Ware RE, Burchinal MR, Kinney TR, Foreman JW (2000) Prevalence and clinical correlates of glomerulopathy in children with sickle cell disease. J Pediatr 136:749–753PubMed
33.
Saraf SL, Molokie RE, Gowhari M, Hassan J, Lash JP, Gordeuk VR (2013) Hyperfiltration is a risk factor for the development of microalbuminuria in sickle cell anemia. Blood 122:1003-03
34.
Maigne G, Ferlicot S, Galacteros F, Belenfant X, Ulinski T, Niaudet P et al (2010) Glomerular lesions in patients with sickle cell disease. Medicine 89:18–27CrossRefPubMed
35.
Zar T, Krishnaswamy J, Yamase HT, Samson W (2011) Membranoproliferative glomerulonephritis in a postpartum woman with sickle cell disease. Iran J Kidney Dis 5:63–65PubMed
36.
Kaze FF, Kengne AP, Atanga LC, Monny Lobe M, Menanga AP, Halle M-P, Chetcha Chemegni B, Ngo Sack F, Kingue S, Ashuntantang G (2013) Kidney function, urinalysis abnormalities and correlates in equatorial Africans with sickle cell disease. Clin Kidney J 6:5–20CrossRef
37.
Bolarinwa RA, Akinlade KS, Kuti MA, Olawale OO, Akinola NO (2012) Renal disease in adult Nigerians with sickle cell anemia: a report of prevalence, clinical features and risk factors. Saudi J Kidney Dis Transplant 23:171–175
38.
Saraf SL, Zhang X, Kanias T, Lash JP, Molokie RE, Oza B et al (2014) Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia. Br J Haematol 164:729–739CrossRefPubMed
39.
Baron BW, Mick R, Baron JM (1994) Hematuria in sickle cell anemia-not always benign: evidence for excess frequency of sickle cell anemia in African Americans with renal cell carcinoma. Acta Haematol 92:119–122CrossRefPubMed
40.
Davis CJ, Mostofi FK, Sesterhenn IA (1995) Renal medullary carcinoma the seventh sickle cell nephropathy. Am J Surg Pathol 19:1–11CrossRefPubMed
41.
Lopez Revuelta K, Ricard Andres MP (2011) Kidney abnormalities in sickle cell disease. Nefrologia 31:591–601PubMed
42.
Wolf RB, Kassim AA, Goodpaster RL, DeBaun MR (2014) Nocturnal enuresis in sickle cell disease. Expert Rev Hematol 7:245–254CrossRefPubMed
43.
da Silva GB Jr, Liborio AB, Daher Ede F (2011) New insights on pathophysiology, clinical manifestations, diagnosis, and treatment of sickle cell nephropathy. Ann Hematol 90:1371–1379CrossRefPubMed
44.
Maurel S, Stankovic Stojanovic K, Avellino V, Girshovich A, Letavernier E, Grateau G et al (2014) Prevalence and correlates of metabolic acidosis among patients with homozygous sickle cell disease. Clin J Am Soc Nephrol 9:648–653CrossRefPubMedPubMedCentral
45.
Sharpe CC, Thein SL (2014) How I treat renal complications in sickle cell disease. Blood 123:3720–3726CrossRefPubMed
46.
Raj VM, Freundlich M, Hamideh D, Alvarez O, Seeherunvong W, Abitbol C et al (2014) Abnormalities in renal tubular phosphate handling in children with sickle cell disease. Pediatr Blood Cancer 61:2267–2270CrossRefPubMed
47.
Audard V, Homs S, Habibi A, Galacteros F, Bartolucci P, Godeau B et al (2010) Acute kidney injury in sickle patients with painful crisis or acute chest syndrome and its relation to pulmonary hypertension. Nephrol Dial Transplant 25:2524–2529CrossRefPubMed
48.
Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C (2005) Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine. 84:363–376CrossRefPubMed
49.
Thomas AN, Pattison C, Serjeant GR (1982) Causes of death in sickle-cell disease in Jamaica. Br Med J (Clin Res Ed) 285:633CrossRef
50.
51.
Baddam S, Aban I, Hilliard L, Howard T, Askenazi D, Lebensburger JD (2017) Acute kidney injury during a pediatric sickle cell vaso-occlusive pain crisis. Pediatr Nephrol 32:1451–1456CrossRefPubMedPubMedCentral
52.
McClellan AC, Luthi JC, Lynch JR, Soucie JM, Kulkarni R, Guasch A et al (2012) High one year mortality in adults with sickle cell disease and end-stage renal disease. Br J Haematol 159:360–367CrossRefPubMedPubMedCentral
53.
Abbott K, Hypolite I, Agodoa L (2002) Sickle cell nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 58:9–15CrossRefPubMed
54.
Sundaram N, Bennett M, Wilhelm J, Kim MO, Atweh G, Devarajan P et al (2011) Biomarkers for early detection of sickle nephropathy. Am J Hematol 86:559–566CrossRefPubMedPubMedCentral
55.
Badr M, El Koumi MA, Ali YF, El-Morshedy S, Almonem NA, Hassan T et al (2013) Renal tubular dysfunction in children with sickle cell haemoglobinopathy. Nephrology 18:299–303CrossRefPubMed
56.
Tharaux PL, Hagege I, Placier S, Vayssairat M, Kanfer A, Girot R et al (2005) Urinary endothelin-1 as a marker of renal damage in sickle cell disease. Nephrol Dial Transplant 20:2408–2413CrossRefPubMed
57.
Hamideh D, Raj V, Harrington T, Li H, Margolles E, Amole F et al (2014) Albuminuria correlates with hemolysis and NAG and KIM-1 in patients with sickle cell anemia. Pediatr Nephrol 29:1997–2003CrossRefPubMed
58.
Sabaa N, de Franceschi L, Bonnin P, Castier Y, Malpeli G, Debbabi H et al (2008) Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest 118:1924–1933CrossRefPubMedPubMedCentral
59.
Kasztan M, Fox BM, Speed JS, De Miguel C, Gohar EY, Townes TM et al (2017) Long-term endothelin—a receptor antagonism provides robust renal protection in humanized sickle cell disease mice. J Am Soc Nephrol 28:2443–2458CrossRefPubMedPubMedCentral
60.
Kormann R, Jannot A-S, Narjoz C, Ribeil J-A, Manceau S, Delville M et al (2017) Roles of APOL1 G1 and G2 variants in sickle cell disease patients: kidney is the main target. Br J Haematol 179:323–335CrossRefPubMed
61.
Saraf SL, Shah BN, Zhang X, Han J, Tayo BO, Abbasi T et al (2016) APOL1, α-thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia. Haematologica 102:e1–e6CrossRefPubMed
62.
Geard A, Pule GD, Chetcha Chemegni B, Ngo Bitoungui VJ, Kengne AP, Chimusa ER et al (2017) Clinical and genetic predictors of renal dysfunctions in sickle cell anaemia in Cameroon. Br J Haematol 178:629–639CrossRefPubMedPubMedCentral
63.
Unal S, Kotan C, Delibas A, Oztas Y, Cystatin C (2013) Beta2 Microglobulin, N-Acetyl-beta-d-glucosaminidase, Retinol-Binding Protein, and Endothelin 1 levels in the evaluation of sickle cell disease nephropathy. Pediatr Hematol Oncol 32:250–257CrossRefPubMed
64.
Alvarez O, Zilleruelo G, Wright D, Montane B, Lopez-Mitnik G (2006) Serum cystatin C levels in children with sickle cell disease. Pediatr Nephrol 21:533–537CrossRefPubMed
65.
dos Santos TE, Goncalves RP, Barbosa MC, da Silva GB Jr., Daher Ede F (2015) Monocyte chemoatractant protein-1: a potential biomarker of renal lesion and its relation with oxidative status in sickle cell disease. Blood Cells Mol Dis 54:297–301CrossRefPubMed
66.
Emokpae M, Abdu A, Gwaram B (2016) Neutrophil-to-lymphocyte, platelet-to-lymphocyte ratios and their association with atherogenic index of plasma in sickle cell nephropathy. J Appl Hematol 7:24–29CrossRef
67.
Anderson S, Meyer TW, Rennke HG, Brenner BM (1985) Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76:612–619CrossRefPubMedPubMedCentral
68.
Falk RJ, Scheinman J, Phillips G, Orringer E, Johnson A, Jennette JC (1992) Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. N Engl J Med 326:910–915CrossRefPubMed
69.
Quinn CT, Saraf SL, Gordeuk VR, Fitzhugh CD, Creary SE, Bodas P et al (2017) Losartan for the nephropathy of sickle cell anemia: a phase-2, multicenter trial. Am J Hematol 92:E520–E528CrossRefPubMedPubMedCentral
70.
Nasr SH, Markowitz GS, Sentman RL, D’Agati VD (2006) Sickle cell disease, nephrotic syndrome, and renal failure. Kidney Int 69:1276–1280CrossRefPubMed
71.
Kasztan M, Sun C-W, Townes TM, Pollock DM (2016) Endothelin-1 mediates glomerular and tubular injury in sickle cell mice. FASEB J 30:1220-7
72.
Brawley OW, Cornelius LJ, Edwards LR, Gamble VN, Green BL, Inturrisi CE et al (2008) NIH consensus development statement on hydroxyurea treatment for sickle cell disease. NIH Consens State Sci Statements 25:1–30PubMed
73.
Allon M, Lawson L, Eckman JR, Delaney V, Bourke E (1988) Effects of nonsteroidal antiinflammatory drugs on renal function in sickle cell anemia. Kidney Int 34:500–506CrossRefPubMed
74.
Nielsen L, Canouï-Poitrine F, Jais J-P, Dahmane D, Bartolucci P, Bentaarit B et al (2016) Morbidity and mortality of sickle cell disease patients starting intermittent haemodialysis: a comparative cohort study with non-Sickle dialysis patients. Br J Haematol 174:148–152CrossRefPubMed
75.
Montgomery R, Zibari G, Hill GS, Ratner LE (1994) Renal transplantation in patients with sickle cell nephropathy. Transplantation 58:618–620CrossRefPubMed
76.
Bleyer AJ, Donaldson LA, McIntosh M, Adams PL (2001) Relationship between underlying renal disease and renal transplantation outcome. Am J Kidney Dis 37:1152–1161CrossRefPubMed
77.
Ojo AO, Govaerts TC, Schmouder RL, Leichtman AB, Leavey SF, Wolfe RA et al (1999) Renal transplantation in end-stage sickle cell nephropathy. Transplantation 67:291–295CrossRefPubMed
78.
Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV et al (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332:1317–1322CrossRefPubMed
79.
Thornburg CD, Dixon N, Burgett S, Mortier NA, Schultz WH, Zimmerman SA et al (2009) A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatr Blood Cancer 52:609–615CrossRefPubMedPubMedCentral
80.
Laurin L-P, Nachman PH, Desai PC, Ataga KI, Derebail VK (2013) Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease. Nephrol Dial Transplant 29:1211–1218CrossRefPubMedPubMedCentral
81.
Aygun B, Mortier NA, Smeltzer MP, Shulkin BL, Hankins JS, Ware RE (2013) Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia. Am J Hematol 88:116–119CrossRefPubMed
82.
Alvarez O, Miller ST, Wang WC, Luo Z, McCarville MB, Schwartz GJ et al (2012) Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatr Blood Cancer 59:668–674CrossRefPubMedPubMedCentral
83.
Bartolucci P, Habibi A, Stehle T, Di Liberto G, Rakotoson MG, Gellen-Dautremer J et al (2015) Six months of hydroxyurea reduces albuminuria in patients with sickle cell disease. J Am Soc Nephrol 27:1847–1853CrossRefPubMedPubMedCentral
84.
Tehseen S, Joiner CH, Lane PA, Yee ME (2017) Changes in urine albumin to creatinine ratio with the initiation of hydroxyurea therapy among children and adolescents with sickle cell disease. Pediatr Blood Cancer 64:e26665CrossRef
85.
Weber ML, Vang D, Velho PE, Gupta P, Crosson JT, Hebbel RP et al (2012) Morphine promotes renal pathology in sickle mice. Int J Nephrol Renov Dis 5:109–118
86.
Weber ML, Chen C, Li Y, Farooqui M, Nguyen J, Poonawala T et al (2013) Morphine stimulates platelet-derived growth factor receptor-beta signalling in mesangial cells in vitro and transgenic sickle mouse kidney in vivo. Br J Anaesth 111:1004–1012CrossRefPubMedPubMedCentral
Metadata
Title
Sickle cell nephropathy: an update on pathophysiology, diagnosis, and treatment
Authors
Essa Hariri
Anthony Mansour
Andrew El Alam
Yazan Daaboul
Serge Korjian
Sola Aoun Bahous
Publication date
01-06-2018
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 6/2018
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-018-1803-3

Other articles of this Issue 6/2018

International Urology and Nephrology 6/2018 Go to the issue

Urology - Original Paper

Additional treatments, satisfaction, symptoms and quality of life in women 1 year after vaginal and abdominal pelvic organ prolapse repair

Nephrology - Original Paper

Health-related quality of life in end-stage renal disease patients: the effects of starting dialysis in the first year after the transition period

Urology - Letter to the Editor

RE: Concordance of renal stone culture: PMUC, RPUC, RSC and post-PCNL sepsis-a non-randomized prospective observation cohort study

Nephrology - Original Paper

Determination of NF-κB and RANKL levels in peripheral blood osteoclast precursor cells in chronic kidney disease patients

Nephrology - Original Paper

Treatment dose and the elimination rates of electrolytes, vitamins, and trace elements during continuous veno-venous hemodialysis (CVVHD)

Urology - Letter to the Editor

Pyeloduodenal fistula complicating xanthogranulomatous pyelonephritis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits